Download PDF
Horm Metab Res 2024; 56(04): 259-260
DOI: 10.1055/a-2256-7180
Editorial

International Roadshow: New Advances in Endocrinology and Metabolic Diseases

Charlotte Steenblock 
1   Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Maha M. Saber-Ayad 
2   College of Medicine, University of Sharjah, United Arab Emirates
,
Stefan R. Bornstein
1   Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
3   School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
4   Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Dear Readers,

Currently, there is a myriad of new developments in the field of endocrinology. In particular, significant strides have been made in the development of poly-agonists for the treatment of type 2 diabetes and obesity [1] [2]. Poly-agonists represent a novel therapeutic approach by combining multiple actions within a single molecule, targeting multiple receptors simultaneously to achieve enhanced efficacy. These innovative compounds aim to address the complex interplay of hormonal pathways involved in glucose regulation and metabolism, offering potential breakthroughs in the management of diabetes and obesity.



Publication History

Article published online:
11 April 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Nauck MA, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 2021; 46: 101102
    CrossrefPubMedGoogle Scholar
  • 2 Tschöp MH, Friedman JM. Seeking satiety: from signals to solutions. Sci Transl Med 2023; 15: eadh4453
    CrossrefPubMedGoogle Scholar
  • 3 Oikonomakos IT, Anjana RM, Mohan V. et al. Recent advances in artificial intelligence-assisted endocrinology and diabetes. Explor Endocri Metab Dis 2023; 1: 16-26
    CrossrefPubMedGoogle Scholar
  • 4 Bornstein SR, Ludwig B, Steenblock C. Progress in islet transplantation is more important than ever. Nat Rev Endocrinol 2022; 18: 389-390
    CrossrefPubMedGoogle Scholar
  • 5 Hartmann-Boyce J, Rees K, Onakpoya I. et al. An update to the overview of reviews: risks of and from SARS-COV-2 infection and COVID-19 in people with diabetes. Diabetes Care 2023; 46: e215-e216
    CrossrefPubMedGoogle Scholar
  • 6 Steenblock C, Toepfner N, Beuschlein F. et al. SARS-CoV-2 infection and its effects on the endocrine system. Best Pract Res Clin Endocrinol Metab 2023; 37: 101761
    CrossrefPubMedGoogle Scholar
  • 7 Perakakis N, Harb H, Hale BG. et al. Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases. Lancet Diabetes Endocrinol 2023; 11: 675-693
    CrossrefPubMedGoogle Scholar
  • 8 Taneera J, Saber-Ayad MM. Preservation of β-cells as a therapeutic strategy for diabetes. Horm Metab Res 2024; 56: 261-271
    PubMedGoogle Scholar
  • 9 Taneera J, Mahgoub E, Qannita R. et al. β-thalassemia and diabetes mellitus: current state and future directions. Horm Metab Res 2024; 56: 272-278
    PubMedGoogle Scholar
  • 10 Schepp F, Schubert U, Schmid J. et al. Mechanistic insights into ferroptotic cell death in pancreatic islets. Horm Metab Res 2024; 56: 279-285
    PubMedGoogle Scholar
  • 11 Schubert U, Lehmann S, Schmid J. et al. The adrenal gland and pancreatic islets - a beneficial endocrine alliance. Horm Metab Res 2024; 56: 286-293
    PubMedGoogle Scholar
  • 12 Toktogulova N, Breidert M, Eschbach J. et al. Energy metabolism in residents in the low- and moderate altitude regions of central Asia with MAFLD and type 2 diabetes mellitus. Horm Metab Res 2024; 56: 294-299
    PubMedGoogle Scholar
  • 13 Gruber S, Stasi E, Boan Pion A. et al. Unawareness of primary aldosteronism as a common cause of hypokalemia – insights from the IPAHK+ trial (incidence of primary aldosteronism in patients with hypokalemia). Horm Metab Res 2024; 56: 300-307
    PubMedGoogle Scholar
  • 14 Steenblock C, Richter S, Lindemann D. et al. Marine sponge-derived secondary metabolites modulate SARSCoV-2 entry mechanisms. Horm Metab Res 2024; 56: 309-317
    PubMedGoogle Scholar
  • 15 Bornstein SR, Cozma D, Kamel M. et al. Long-COVID, metabolic and endocrine disease. Horm Metab Res 2022; 54: 562-566
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Kronstein-Wiedemann R, Tausche K, Kolditz M. et al. Long-COVID is associated with impaired red blood cell function. Horm Metab Res 2024; 56: 318-323
    PubMedGoogle Scholar